$ACUT

Accustem Sciences Inc.

CIK:0001850767|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
OTHER INCOME	$ 98,400		$ 98,400
OPERATING EXPENSES
Research and development expenses	43,712	60,204	163,237	88,550
General and administrative expenses	307,261	341,199	673,619	753,261
Total operating expenses	350,973	401,403	836,856	841,811
LOSS FROM OPERATIONS	(252,573)	(401,403)	(738,456)	(841,811)
NET LOSS	$ (252,573)	$ (401,403)	$ (738,456)	$ (841,811)
Net loss per share attributable to common stockholders, basic	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.06)
Net loss per share attributable to common stockholders, diluted	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.06)
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic	16,072,267	16,072,267	16,072,267	14,407,244
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, diluted	16,072,267	16,072,267	16,072,267	14,407,244

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating Activities
Net loss	$ (738,456)	$ (841,811)
Adjustments to reconcile net loss to net cash used in (provided by) operating activities
Depreciation		418
Share-based compensation	22,464	41,348
Expenses settled in stock		79,000
Change in operating assets and liabilities:
Prepaid expenses	30,311	56,567
Accounts payable	(88,221)	55,310
Related party payable	131,836	350,769
Accrued expenses	19,040	(10,216)
Net cash used in (provided by) operating activities	(623,026)	(268,615)
Financing Activities
Advances from related party	670,000	347,000
Payments on note payable	(47,975)	(52,090)
Net cash used in (provided by) financing activities	622,025	294,910
(Decrease)/Increase in cash	(1,001)	26,295
Cash, beginning of period	13,929	5,046
Cash, end of period	12,928	31,341
Supplemental disclosure of noncash investing and financing activities
Issuance of Note Payable for payment of prepaid expense	87,409	92,597
Cash paid for interest	660	780
Shares issued pending non-cash transaction	$ 1,500,000	$ 1,500,000

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash	$ 12,928	$ 13,929
Prepaid expenses	93,276	35,517
Total Current Assets	106,204	49,446
Equipment, net
Other non-current assets	1,500,000	1,500,000
TOTAL ASSETS	1,606,204	1,549,446
Current Liabilities
Accounts payable	615,592	703,812
Related party payable	5,024,674	4,222,838
Accrued expenses	20,914	1,875
Note Payable	62,641	22,546
Total Current Liabilities	5,723,821	4,951,071
TOTAL LIABILITIES	5,723,821	4,951,071
Shareholders’ Equity
Preferred stock $.001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock $.001 par value; 150,000,000 shares authorized; 16,072,267 shares issued and outstanding as of June 30, 2026 and 16,072,267 shares issued and outstanding as of December 31, 2025	16,072	16,072
Additional paid-in capital	6,387,910	6,365,446
Accumulated deficit	(10,521,599)	(9,783,143)
TOTAL SHAREHOLDERS’ EQUITY	(4,117,617)	(3,401,625)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 1,606,204	$ 1,549,446